Evolus, Inc. Announces Estyme® License Expansion to Canada, Australia & NZ

What Happened
Evolus, Inc. (through wholly owned subsidiary Evolus Pharma B.V.) announced on August 3, 2026 an amendment to its December 20, 2023 License, Supply and Distribution Agreement with Symatese Aesthetics S.A.S. The Amendment expands the licensed territory to include Canada and Australia/New Zealand and grants Evolus Europe exclusive rights to commercialize and distribute the full line of Estyme® injectable hyaluronic acid gels in those territories. The Company furnished a press release about the Amendment on August 4, 2026 (Exhibit 99.1 to the 8-K).

Key Details

• Amendment executed: August 3, 2026; original agreement dated December 20, 2023.
• Territory added: (i) Canada and (ii) Australia & New Zealand (combined).
• Payment terms: Evolus Europe to pay €920,000 upfront upon signing and up to an additional €1.38 million upon receipt of certain regulatory approvals.
• Regulatory and development responsibilities: Symatese will fund and manage required development and regulatory activities in the added territories.
• Term: 15-year initial term for each new territory measured from first applicable regulatory approval, with automatic successive five-year renewals per the Agreement.

Why It Matters
This amendment expands Evolus’s potential commercial footprint for Estyme® into three additional markets, creating a clearer pathway to generate product sales outside existing territories if regulatory approvals are obtained. The financial commitment from Evolus (€920k upfront plus contingent €1.38M) is modest relative to a full acquisition, while Symatese retaining responsibility for regulatory work reduces Evolus’s near-term development costs. Investors should note the approval-dependent nature of the deal—commercial benefits hinge on successful regulatory clearances in each territory.